FDA will consider expanded use of Astellas' cancer drug erlotinib

01/18/2013 | Pharmaceutical Business Review Online

Astellas Pharma said the FDA has accepted its supplemental new drug application for Tarceva, or erlotinib, as a first-line treatment for EGFR-positive metastatic or locally advanced nonsmall-cell lung cancer. The application was given priority-review designation.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA